CRISPR Therapeutics AG
CRSP57.840USD
+1.580+2.81%
Close 09/15, 16:00（ET）Quotes delayed by 15 min
5.11BMarket Cap
LossP/E TTM
More Details of CRISPR Therapeutics AG Company
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Company Info
Ticker SymbolCRSP
Company nameCRISPR Therapeutics AG
IPO dateOct 19, 2016
CEODr. Samarth Kulkarni, Ph.D.
Number of employees393
Security typeOrdinary Share
Fiscal year-endOct 19
AddressBaarerstrasse 14
CityZUG
Stock exchangeNASDAQ Global Market Consolidated
CountrySwitzerland
Postal code6300
Phone41415613279
Websitehttps://crisprtx.com/
Ticker SymbolCRSP
IPO dateOct 19, 2016
CEODr. Samarth Kulkarni, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
292.63K
+4.25%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Sandesh Mahatme
Mr. Sandesh Mahatme
Independent Director
Independent Director
--
--
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
--
--
Dr. Maria Fardis, Ph.D.
Dr. Maria Fardis, Ph.D.
Independent Director
Independent Director
--
--
Dr. H. Edward Fleming, Jr., M.D.
Dr. H. Edward Fleming, Jr., M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
292.63K
+4.25%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
11.20%
Capital International Investors
6.15%
BlackRock Institutional Trust Company, N.A.
5.96%
T. Rowe Price Investment Management, Inc.
4.05%
State Street Global Advisors (US)
3.60%
Other
69.05%
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
11.20%
Capital International Investors
6.15%
BlackRock Institutional Trust Company, N.A.
5.96%
T. Rowe Price Investment Management, Inc.
4.05%
State Street Global Advisors (US)
3.60%
Other
69.05%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.51%
Investment Advisor/Hedge Fund
21.68%
Hedge Fund
3.78%
Venture Capital
3.45%
Research Firm
3.18%
Individual Investor
1.64%
Bank and Trust
1.57%
Pension Fund
0.45%
Sovereign Wealth Fund
0.45%
Other
17.31%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
949
75.06M
82.87%
+271.52K
2025Q1
952
68.11M
78.87%
-5.61M
2024Q4
955
68.20M
79.52%
-1.17M
2024Q3
962
64.14M
75.29%
-1.47M
2024Q2
976
63.22M
74.44%
-1.89M
2024Q1
986
62.72M
74.09%
+4.47M
2023Q4
985
55.14M
69.41%
-4.96M
2023Q3
992
55.19M
69.50%
-6.68M
2023Q2
1037
54.86M
69.51%
-8.28M
2023Q1
1053
55.90M
70.89%
-6.49M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARK Investment Management LLC
10.17M
11.77%
+1.19M
+13.29%
Mar 31, 2025
Capital International Investors
6.07M
7.03%
-2.67M
-30.54%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.41M
2.8%
-100.08K
-3.98%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
3.80M
4.4%
-13.61K
-0.36%
Mar 31, 2025
State Street Global Advisors (US)
2.41M
2.79%
-80.26K
-3.22%
Mar 31, 2025
Two Sigma Investments, LP
1.99M
2.3%
+1.60M
+407.93%
Mar 31, 2025
Orbis Investment Management Ltd.
1.56M
1.81%
+86.81K
+5.88%
Mar 31, 2025
UBS Financial Services, Inc.
1.73M
2%
-94.39K
-5.18%
Mar 31, 2025
Amova Asset Management Co., Ltd.
2.54M
2.94%
-205.79K
-7.49%
Mar 31, 2025
Amova Asset Management Americas, Inc
2.54M
2.94%
-205.79K
-7.49%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
ARK Genomic Revolution ETF
9.19%
Global X Genomics & Biotechnology ETF
5.61%
ARK Innovation ETF
4.11%
AXS Green Alpha ETF
3.95%
WisdomTree BioRevolution Fund
3.07%
SPDR S&P Biotech ETF
1.51%
Amplify Small-Mid Cap Equity ETF
1.07%
Direxion Daily S&P Biotech Bull 3X Shares
0.86%
iShares Exponential Technologies ETF
0.52%
iShares Biotechnology ETF
0.41%
View more
ARK Genomic Revolution ETF
Proportion9.19%
Global X Genomics & Biotechnology ETF
Proportion5.61%
ARK Innovation ETF
Proportion4.11%
AXS Green Alpha ETF
Proportion3.95%
WisdomTree BioRevolution Fund
Proportion3.07%
SPDR S&P Biotech ETF
Proportion1.51%
Amplify Small-Mid Cap Equity ETF
Proportion1.07%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.86%
iShares Exponential Technologies ETF
Proportion0.52%
iShares Biotechnology ETF
Proportion0.41%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
